TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23963307

Group type: EXPERIMENTAL
Intervention: Drospirenone 0.25 mg/17β‐estradiol 0.5 mg
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Drospirenone 0.5 mg/17β‐estradiol 0.5 mg
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: 17β‐estradiol 0.3 mg
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Drospirenone/17β‐estradiol combinations
Number of subjects: 735

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Drospirenone/17β‐estradiol
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Active treatments
Number of subjects: 735
Study: 22644587

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Telephone support
Number of subjects: 146
Study: 20973952

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 18952561

Group type: EXPERIMENTAL
Intervention: 4 courses of anthracycline-based chemotherapy followed by 4 courses of docetaxel or paclitaxel in combination with trastuzumab, followed by 14 additional courses of trastuzumab (total of 18 doses)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: 3 courses of 3-weekly docetaxel in combination with weekly trastuzumab (total of 9 doses) followed by 3 courses of 5-fluorouracil/epirubicin/cyclophosphamide
Number of subjects: 2500
Study: 17160151

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 0
Study: 12803277

Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 401
Study: 10861325

Group type: EXPERIMENTAL
Intervention: Bacille Calmette‐Guérin vaccine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Case-control studies
Number of subjects: 13
Study: 8971495

Group type: EXPERIMENTAL
Intervention: Phosphocreatine (PCr) administration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (isotonic NaCl solution)
Number of subjects: 8
Study: 1482151

Group type: EXPERIMENTAL
Intervention: Piperacillin plus amikacin
Number of subjects: 170

Group type: COMPARATOR
Intervention: Ceftazidime plus amikacin
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Piperacillin plus amikacin with vancomycin
Number of subjects: 170

Group type: COMPARATOR
Intervention: Ceftazidime plus amikacin with vancomycin
Number of subjects: 170
Study: 4051146

Group type: EXPERIMENTAL
Intervention: Minocromil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30444137

Group type: EXPERIMENTAL
Intervention: Irbesartan (switch group)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Continue same ARB (continue group)
Number of subjects: 85
Study: 30352784

Group type: EXPERIMENTAL
Intervention: Selinexor (60, 80, or 100 mg orally) plus bortezomib (1.3 mg/m2 subcutaneously) and dexamethasone (20 mg orally) once or twice weekly in 21- or 35-day cycles.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Selinexor (100 mg once weekly), bortezomib (1.3 mg/m2 once weekly for 4 weeks), and dexamethasone (40 mg once weekly) per 35-day cycle (recommended phase 2 dose).
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Selinexor plus bortezomib and dexamethasone (SVd).
Number of subjects: 42
Study: 27247261

Group type: EXPERIMENTAL
Intervention: so-tDCS (0.75 Hz; max. current density 0.522 mA/cm²)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 21
Study: 25263038

Group type: EXPERIMENTAL
Intervention: Multifocal toric intraocular lens (IOL) implantation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nontoric multifocal IOL combined with peripheral corneal relaxing incisions (PCRIs)
Number of subjects: 30
Study: 22919238

Group type: EXPERIMENTAL
Intervention: Rectal indomethacin administered immediately after ERCP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20652391

Group type: EXPERIMENTAL
Intervention: Basic UV photo/photoaging intervention
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Intervention plus downward social comparison
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Intervention plus upward social comparison
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study: 17604800

Group type: EXPERIMENTAL
Intervention: Autologous myoblasts and fibroblasts
Number of subjects: 63

Group type: COMPARATOR
Intervention: Collagen
Number of subjects: 63
Study: 16137981

Group type: EXPERIMENTAL
Intervention: Reduced sulphurous mineral water baths
Number of subjects: 60

Group type: COMPARATOR
Intervention: Modified tap water baths
Number of subjects: 60
Study: 12214938

Group type: EXPERIMENTAL
Intervention: Artemether (1.6 mg/kg body wt., repeated after 12 hrs and then daily for four days)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Quinine (10 mg/kg body wt in 10 ml/kg body wt of 5% dextrose in 0.9% saline intravenously, repeated every 8 hrs and changed to oral administration when the child was able to drink to finish seven days)
Number of subjects: 77
Study: 9862595

Group type: EXPERIMENTAL
Intervention: 2-octylcyanoacrylate
Number of subjects: 124

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 124
Study: 8588960

Group type: EXPERIMENTAL
Intervention: Oral cefadroxil
Number of subjects: 559

Group type: COMPARATOR
Intervention: Intravenous cefuroxime
Number of subjects: 559
Study: 2633082

Group type: EXPERIMENTAL
Intervention: CP-enriched cardioplegia at a concentration of 10 mmol/l
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plain cardioplegia
Number of subjects: 40
Study: 876671

Group type: EXPERIMENTAL
Intervention: Internal group with personal control instructions
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: External group with environmental control instructions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Models who were tolerant, intolerant, or inactive
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subsequent disclosure of the model's roles
Number of subjects: 50
Study: 29915994

Group type: EXPERIMENTAL
Intervention: Positive Thinking Group (PTC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Self-Regulation Condition (SRC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cancer-Fact Group (CFC)
Number of subjects: 90
Study: 28571019

Group type: EXPERIMENTAL
Intervention: High-Flux Hemodialysis (HD)
Number of subjects: 0
Study: 25581584

Group type: EXPERIMENTAL
Intervention: MAL-PDT
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Imiquimod cream
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Fluorouracil cream
Number of subjects: 601
Study: 23484178

Group type: EXPERIMENTAL
Intervention: Bio‐Oss
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NanoBone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no filling)
Number of subjects: 10
Study: 21372734

Group type: EXPERIMENTAL
Intervention: High level of social support
Number of subjects: 333
Study: 19462697

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ) summary score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not good QoL (< 75) in NYHA II patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KCCQ summary scores
Number of subjects: 0
Study: 17941858

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (up to 105 mg/day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (over 90 mg/day)
Number of subjects: 6
Study: 15001200

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/HCTZ 20/12.5 mg
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/HCTZ 40/25 mg
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 11737935

Group type: EXPERIMENTAL
Intervention: Surfactant administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9787943

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at a dose of 2 g/d
Number of subjects: 133

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (CMV disease-free patients)
Number of subjects: 133
Study: 8011800

Group type: EXPERIMENTAL
Intervention: Buspirone (30 mg orally)
Number of subjects: 73
Study: 2475681

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil (240-mg tablets), given once or twice daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil
Number of subjects: 14
Study: 367715

Group type: EXPERIMENTAL
Intervention: Syndol (analgesic combination)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28668970

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) for 2 weeks, 6 hours daily bilateral calf IPC applied under an orthosis on the injured side.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Treatment-as-usual (plaster cast without IPC) for 2 weeks.
Number of subjects: 150
Study: 26930156

Group type: EXPERIMENTAL
Intervention: Severe PE/GH
Number of subjects: 4323

Group type: EXPERIMENTAL
Intervention: Mild PE/GH
Number of subjects: 4323

Group type: COMPARATOR
Intervention: Normotensive women
Number of subjects: 4323
Study: 23937924

Group type: EXPERIMENTAL
Intervention: Surgeon delivered psoas compartment block
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no psoas compartment block)
Number of subjects: 53
Study: 21775876

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 2532

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 220 mg twice daily
Number of subjects: 2532

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2532
Study: 21520659

Group type: EXPERIMENTAL
Intervention: Ileo colic intubation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Resection anastomosis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ileostomy
Number of subjects: 40
Study: 18946890

Group type: EXPERIMENTAL
Intervention: Nateglinide with valsartan
Number of subjects: 9518

Group type: EXPERIMENTAL
Intervention: Nateglinide with valsartan-placebo
Number of subjects: 9518

Group type: EXPERIMENTAL
Intervention: Nateglinide-placebo with valsartan
Number of subjects: 9518

Group type: COMPARATOR
Intervention: Nateglinide-placebo with valsartan-placebo
Number of subjects: 9518
Study: 15978968

Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (200 IU/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11840366

Group type: COMPARATOR
Intervention: Synthetically modified cellulosic (SMC) membrane after 3 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Synthetically modified cellulosic (SMC) membrane after 6 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cellulose diacetate (CD) membrane after 3 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cellulose diacetate (CD) membrane after 6 months
Number of subjects: 18
Study: 10386278

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1 to 1.5 mg/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 45
Study: 9038563

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 18

Group type: COMPARATOR
Intervention: Calcium and calciferol
Number of subjects: 18
Study: 1763654

Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bromocryptine (5 mg daily)
Number of subjects: 25
Study: 6353478

Group type: EXPERIMENTAL
Intervention: Iopamidol 370
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iopamidol 300
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher concentration of non-ionic contrast media
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-ionic contrast media
Number of subjects: 0
Study: 30967104

Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern adherence
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Normalization of body weight
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 96
Study: 31581789

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13885

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13885

Group type: COMPARATOR
Intervention: Control (Clopidogrel)
Number of subjects: 13885

Group type: EXPERIMENTAL
Intervention: All procedures (peripheral revascularization, coronary revascularization, lower extremity amputation)
Number of subjects: 13885
Study: 26637841

Group type: EXPERIMENTAL
Intervention: ADHD + ASD (n=93)
Number of subjects: 392

Group type: COMPARATOR
Intervention: ADHD (n=299)
Number of subjects: 392
Study: 26607249

Group type: EXPERIMENTAL
Intervention: Sodium nitrite (80 or 160 mg/day, capsules, TheraVasc)
Number of subjects: 0
Study: 24412929

Group type: EXPERIMENTAL
Intervention: Insulin glulisine (GLU)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Insulin aspart (ASP)
Number of subjects: 56
Study: 22240636

Group type: EXPERIMENTAL
Intervention: Pomegranate seed oil (PGS) 30 mg, 127 μg of steroidal phytoestrogens per dose, taken twice daily for 12 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pomegranate seed oil (PGS)
Number of subjects: 81
Study: 19925608

Group type: EXPERIMENTAL
Intervention: Radiation protection cabin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard protection with a 0.5 mm lead-equivalent apron (control)
Number of subjects: 60
Study: 18575579

Group type: EXPERIMENTAL
Intervention: D3 receptor‐preferring agonist pramipexole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15851283

Group type: EXPERIMENTAL
Intervention: DDD pacemaker implantation
Number of subjects: 48
Study: 12403400

Group type: EXPERIMENTAL
Intervention: Short dialysis (150 minutes)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Long dialysis (240 minutes)
Number of subjects: 14
Study: 10454450

Group type: EXPERIMENTAL
Intervention: DHA (4 g/d)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: EPA (4 g/d)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 59
Study: 8634157

Group type: EXPERIMENTAL
Intervention: 0.234% NaF/silica/10% xylitol dentifrice
Number of subjects: 2630

Group type: COMPARATOR
Intervention: 0.243% NaF/silica dentifrice (positive control)
Number of subjects: 2630
Study: 2185155

Group type: EXPERIMENTAL
Intervention: Clavulanate‐potentiated amoxicillin (Augmentin)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Fosfomycin trometamol
Number of subjects: 141
Study: 7466380

Group type: EXPERIMENTAL
Intervention: Active hemodialysis
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham dialysis
Number of subjects: 8
Study: 30303832

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0
Study: 28150431

Group type: EXPERIMENTAL
Intervention: Terminally branching scheme
Number of subjects: 86

Group type: COMPARATOR
Intervention: Hybrid scheme
Number of subjects: 86
Study: 26558386

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation combined with constraint-induced movement therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation with constraint-induced movement therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation and CIMT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neuroimaging
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation techniques
Number of subjects: 20
Study: 23897942

Group type: EXPERIMENTAL
Intervention: Lidocaine-epinephrine-tetracaine
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 21252503

Group type: EXPERIMENTAL
Intervention: Hemofiltration (HF)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Low-flux Hemodialysis (HD)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Comparison of HF and HD
Number of subjects: 34
Study: 19432500

Group type: EXPERIMENTAL
Intervention: TZP-101 single doses (160-600 microg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TZP-101 multiple doses (80-600 microg/kg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TZP-101
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TZP-101 protein binding
Number of subjects: 0
Study: 20801260

Group type: EXPERIMENTAL
Intervention: Submaximal tests (step test and grip strength)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Submaximal tests (step test and grip strength) combined with body weight
Number of subjects: 183
Study: 16143120

Group type: EXPERIMENTAL
Intervention: Certolizumab 100 mg
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Certolizumab 200 mg
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Certolizumab 400 mg
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Certolizumab 400 mg (in patients with baseline C-reactive protein levels of 10 mg/L or greater)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo (in patients with baseline C-reactive protein levels of 10 mg/L or greater)
Number of subjects: 292
Study: 11865835

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF) 1600 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10206296

Group type: EXPERIMENTAL
Intervention: 5‐Fluorouracil (5FU)‐based chemotherapy
Number of subjects: 497
Study: 7767666

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 33359

Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Number of subjects: 33359

Group type: EXPERIMENTAL
Intervention: RITA randomization
Number of subjects: 33359

Group type: COMPARATOR
Intervention: Referral for myocardial revascularization
Number of subjects: 33359

Group type: COMPARATOR
Intervention: Myocardial revascularization
Number of subjects: 33359
Study: 2159990

Group type: EXPERIMENTAL
Intervention: Desciclovir, 250 mg three times a day for 14 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Desciclovir
Number of subjects: 14
Study: 374208

Group type: EXPERIMENTAL
Intervention: Cerebral vasoactive and cerebral metabolic active substances
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12925554

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (diuretic)
Number of subjects: 9392

Group type: COMPARATOR
Intervention: Doxazosin (alpha-blocker)
Number of subjects: 9392
Study: 28918674

Group type: EXPERIMENTAL
Intervention: 150mg Fruitflow
Number of subjects: 12
Study: 27084978

Group type: EXPERIMENTAL
Intervention: USL255 (topiramate extended-release capsules) up to 400 mg/day
Number of subjects: 217
Study: 23909985

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day plus pioglitazone 15 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day plus pioglitazone 30 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day plus pioglitazone 45 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: All combination-treated groups
Number of subjects: 7

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 7
Study: 22419733

Group type: EXPERIMENTAL
Intervention: Insulin treatment during euglycemic-hyperinsulinemic clamp
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Insulin treatment during hyperglycemic-hyperinsulinemic clamp
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: High glucose and insulin treatment in monocytes
Number of subjects: 157

Group type: COMPARATOR
Intervention: Comparison of NPRC gene expression in VAT vs SAT
Number of subjects: 157
Study: 21287477

Group type: EXPERIMENTAL
Intervention: Lidocaine 5% (75 mg) and 10 micrograms sufentanil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lidocaine 5% (75 mg) and 5 micrograms sufentanil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lidocaine 5% (75 mg) and 2 ml of normal saline (control group)
Number of subjects: 90
Study: 18385198

Group type: EXPERIMENTAL
Intervention: Temsirolimus i.v. 25 mg weekly
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Temsirolimus i.v. 15 mg weekly plus interferon s.c. 6 MU thrice weekly
Number of subjects: 208

Group type: COMPARATOR
Intervention: Interferon alfa (IFN) s.c. up to 18 MU thrice weekly
Number of subjects: 208
Study: 15765388

Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis 35624
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius UCC4331
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (malted milk drink)
Number of subjects: 77
Study: 11813224

Group type: EXPERIMENTAL
Intervention: Anti-lymphocyte antibody induction therapy
Number of subjects: 628

Group type: COMPARATOR
Intervention: Group-level analyses
Number of subjects: 628
Study: 10028216

Group type: EXPERIMENTAL
Intervention: Fluoxetine 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8566881

Group type: EXPERIMENTAL
Intervention: Levosulpiride (LS) regimen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metoclopramide (MTC) regimen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Levosulpiride (LS) regimen (higher dose on day 8)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metoclopramide (MTC) regimen (higher dose on day 8)
Number of subjects: 20
Study: 2147736

Group type: EXPERIMENTAL
Intervention: 0.5 mg norgestrel + (Cyclo‐Progynova)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 1 mg cyproterone acetate (SH D 461 A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 49
Study: 436602

Group type: EXPERIMENTAL
Intervention: Isoprodian with rifampicin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isoniazid, ethambutol, and rifampicin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 31016671

Group type: EXPERIMENTAL
Intervention: Gentamicin 5 mg/kg based on lean body weight in morbidly obese individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gentamicin 5 mg/kg based on total body weight in non-obese individuals
Number of subjects: 0